{"id":297346,"date":"2025-11-04T00:00:00","date_gmt":"2025-11-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0041-2024-biopharma-systemic-lupus-erythematosus-current-treatment-treatment-algorithms-claims\/"},"modified":"2026-04-24T11:14:25","modified_gmt":"2026-04-24T11:14:25","slug":"algoim0041-2025-biopharma-systemic-lupus-erythematosus-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0041-2025-biopharma-systemic-lupus-erythematosus-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Systemic Lupus Erythematosus &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Systemic Lupus Erythematosus (US)"},"content":{"rendered":"<p>Systemic lupus erythematosus (<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>) is an autoimmune disease that affects multiple organ systems. <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> symptoms range from general malaise to serious <abbr title=\"central nervous system\">CNS<\/abbr> and renal manifestations. Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay treatments for <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>. Unfortunately, many patients with <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> fail to respond to these therapies and\/or experience significant adverse events. Clinicians may then prescribe other available agents, such as the biologics Benlysta (GlaxoSmithKline), Saphnelo (AstraZeneca), Rituxan (Roche; off label), and Orencia (<abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>; off label) or the novel calcineurin inhibitor Lupkynis (Aurinia). This content gives manufacturers of current treatments and developers of novel <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> agents insight into the use of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> drugs and market trends in the <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> space.<\/p>\n<p><strong><strong>Questions answered<\/strong><\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> patients?<\/li>\n<li>How have Benlysta, Saphnelo, and Lupkynis been integrated into the treatment algorithm, and what is their source of business?<\/li>\n<li>What percentage of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Markets covered:<\/strong> United States<\/p>\n<p class=\"text-align-left\"><strong>Key companies:<\/strong> GlaxoSmithKline, AstraZeneca, Aurinia<\/p>\n<p class=\"text-align-left\"><strong>Key drugs: <\/strong>Benlysta, Rituxan, Saphnelo, Lupkynis, mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide, hydroxychloroquine, leflunomide, methotrexate, tacrolimus, mycophenolate sodium, Orencia<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<div>\n<ul class=\"BulletListStyle1 SCXW263284921 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><b>Product enhancement<\/b><b> <\/b><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n<\/div>\n<p><strong>Key feature<\/strong><\/p>\n<p>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n","protected":false},"template":"","class_list":["post-297346","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-systemic-lupus-erythematosus","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/297346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/297346\/revisions"}],"predecessor-version":[{"id":556419,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/297346\/revisions\/556419"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=297346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}